vs
伯克希尔·哈撒韦（HEI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
伯克希尔·哈撒韦的季度营收约是Revvity的1.6倍（$1.2B vs $772.1M），伯克希尔·哈撒韦净利率更高（15.6% vs 12.7%，领先2.8%），伯克希尔·哈撒韦同比增速更快（19.3% vs 5.9%），伯克希尔·哈撒韦自由现金流更多（$268.5M vs $161.8M），过去两年伯克希尔·哈撒韦的营收复合增速更高（16.2% vs 9.0%）
伯克希尔·哈撒韦是总部位于美国内布拉斯加州奥马哈的跨国综合控股集团，最初主营纺织品制造，1965年起在董事长兼首席执行官沃伦·巴菲特、副董事长查理·芒格的带领下转型为多元化企业集团，2026年初格雷格·阿贝尔接任首席执行官，巴菲特个人持有公司38.4%的A类有投票权股份，对应15.1%的整体经济权益。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HEI vs RVTY — 直观对比
营收规模更大
HEI
是对方的1.6倍
$772.1M
营收增速更快
HEI
高出13.5%
5.9%
净利率更高
HEI
高出2.8%
12.7%
自由现金流更多
HEI
多$106.7M
$161.8M
两年增速更快
HEI
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $188.3M | $98.4M |
| 毛利率 | 40.2% | — |
| 营业利润率 | 23.1% | 14.5% |
| 净利率 | 15.6% | 12.7% |
| 营收同比 | 19.3% | 5.9% |
| 净利润同比 | 34.8% | 3.9% |
| 每股收益（稀释后） | $1.32 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HEIRVTY
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $1.0B | $729.4M | ||
| Q3 24 | $992.2M | $684.0M | ||
| Q2 24 | $955.4M | $691.7M | ||
| Q1 24 | $896.4M | $649.9M |
净利润HEIRVTY
| Q4 25 | $188.3M | $98.4M | ||
| Q3 25 | $177.3M | $46.7M | ||
| Q2 25 | $156.8M | $53.9M | ||
| Q1 25 | $168.0M | $42.2M | ||
| Q4 24 | $139.7M | $94.6M | ||
| Q3 24 | $136.6M | $94.4M | ||
| Q2 24 | $123.1M | $55.4M | ||
| Q1 24 | $114.7M | $26.0M |
毛利率HEIRVTY
| Q4 25 | 40.2% | — | ||
| Q3 25 | 39.8% | 53.6% | ||
| Q2 25 | 39.9% | 54.5% | ||
| Q1 25 | 39.4% | 56.5% | ||
| Q4 24 | 38.9% | — | ||
| Q3 24 | 39.2% | 56.3% | ||
| Q2 24 | 38.9% | 55.7% | ||
| Q1 24 | 38.7% | 54.6% |
营业利润率HEIRVTY
| Q4 25 | 23.1% | 14.5% | ||
| Q3 25 | 23.1% | 11.7% | ||
| Q2 25 | 22.6% | 12.6% | ||
| Q1 25 | 22.0% | 10.9% | ||
| Q4 24 | 21.6% | 16.3% | ||
| Q3 24 | 21.8% | 14.3% | ||
| Q2 24 | 21.9% | 12.4% | ||
| Q1 24 | 20.1% | 6.8% |
净利率HEIRVTY
| Q4 25 | 15.6% | 12.7% | ||
| Q3 25 | 15.5% | 6.7% | ||
| Q2 25 | 14.3% | 7.5% | ||
| Q1 25 | 16.3% | 6.4% | ||
| Q4 24 | 13.8% | 13.0% | ||
| Q3 24 | 13.8% | 13.8% | ||
| Q2 24 | 12.9% | 8.0% | ||
| Q1 24 | 12.8% | 4.0% |
每股收益（稀释后）HEIRVTY
| Q4 25 | $1.32 | $0.86 | ||
| Q3 25 | $1.26 | $0.40 | ||
| Q2 25 | $1.12 | $0.46 | ||
| Q1 25 | $1.20 | $0.35 | ||
| Q4 24 | $1.00 | $0.77 | ||
| Q3 24 | $0.97 | $0.77 | ||
| Q2 24 | $0.88 | $0.45 | ||
| Q1 24 | $0.82 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $217.8M | $919.9M |
| 总债务越低越好 | $2.2B | — |
| 股东权益账面价值 | $4.3B | $7.3B |
| 总资产 | $8.5B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.50× | — |
8季度趋势，按日历期对齐
现金及短期投资HEIRVTY
| Q4 25 | $217.8M | $919.9M | ||
| Q3 25 | $261.9M | $931.4M | ||
| Q2 25 | $242.3M | $991.8M | ||
| Q1 25 | $165.5M | $1.1B | ||
| Q4 24 | $162.1M | $1.2B | ||
| Q3 24 | $202.9M | $1.2B | ||
| Q2 24 | $204.2M | $2.0B | ||
| Q1 24 | $196.3M | $1.7B |
总债务HEIRVTY
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.5B | — |
股东权益HEIRVTY
| Q4 25 | $4.3B | $7.3B | ||
| Q3 25 | $4.1B | $7.4B | ||
| Q2 25 | $4.0B | $7.6B | ||
| Q1 25 | $3.7B | $7.6B | ||
| Q4 24 | $3.6B | $7.7B | ||
| Q3 24 | $3.5B | $7.9B | ||
| Q2 24 | $3.4B | $7.9B | ||
| Q1 24 | $3.3B | $7.8B |
总资产HEIRVTY
| Q4 25 | $8.5B | $12.2B | ||
| Q3 25 | $8.5B | $12.1B | ||
| Q2 25 | $8.1B | $12.4B | ||
| Q1 25 | $7.9B | $12.4B | ||
| Q4 24 | $7.6B | $12.4B | ||
| Q3 24 | $7.4B | $12.8B | ||
| Q2 24 | $7.4B | $13.4B | ||
| Q1 24 | $7.3B | $13.4B |
负债/权益比HEIRVTY
| Q4 25 | 0.50× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.57× | — | ||
| Q1 25 | 0.63× | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.76× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $295.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $268.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 22.2% | 21.0% |
| 资本支出强度资本支出/营收 | 2.2% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.57× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $861.4M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HEIRVTY
| Q4 25 | $295.3M | $182.0M | ||
| Q3 25 | $231.2M | $138.5M | ||
| Q2 25 | $204.7M | $134.3M | ||
| Q1 25 | $203.0M | $128.2M | ||
| Q4 24 | $205.6M | $174.2M | ||
| Q3 24 | $214.0M | $147.9M | ||
| Q2 24 | $141.1M | $158.6M | ||
| Q1 24 | $111.7M | $147.6M |
自由现金流HEIRVTY
| Q4 25 | $268.5M | $161.8M | ||
| Q3 25 | $218.5M | $120.0M | ||
| Q2 25 | $188.7M | $115.5M | ||
| Q1 25 | $185.7M | $112.2M | ||
| Q4 24 | $189.5M | $149.8M | ||
| Q3 24 | $198.1M | $125.6M | ||
| Q2 24 | $128.2M | $136.6M | ||
| Q1 24 | $98.3M | $129.7M |
自由现金流率HEIRVTY
| Q4 25 | 22.2% | 21.0% | ||
| Q3 25 | 19.0% | 17.2% | ||
| Q2 25 | 17.2% | 16.0% | ||
| Q1 25 | 18.0% | 16.9% | ||
| Q4 24 | 18.7% | 20.5% | ||
| Q3 24 | 20.0% | 18.4% | ||
| Q2 24 | 13.4% | 19.7% | ||
| Q1 24 | 11.0% | 20.0% |
资本支出强度HEIRVTY
| Q4 25 | 2.2% | 2.6% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 1.5% | 2.6% | ||
| Q1 25 | 1.7% | 2.4% | ||
| Q4 24 | 1.6% | 3.4% | ||
| Q3 24 | 1.6% | 3.3% | ||
| Q2 24 | 1.4% | 3.2% | ||
| Q1 24 | 1.5% | 2.7% |
现金转化率HEIRVTY
| Q4 25 | 1.57× | 1.85× | ||
| Q3 25 | 1.30× | 2.97× | ||
| Q2 25 | 1.31× | 2.49× | ||
| Q1 25 | 1.21× | 3.03× | ||
| Q4 24 | 1.47× | 1.84× | ||
| Q3 24 | 1.57× | 1.57× | ||
| Q2 24 | 1.15× | 2.87× | ||
| Q1 24 | 0.97× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HEI
| Aftermarket Replacement Parts | $510.0M | 42% |
| Electronic Componentsfor Defense Spaceand Aerospace | $311.8M | 26% |
| Defenseand Space | $170.6M | 14% |
| Specialty Products | $118.9M | 10% |
| Other Electronic Components | $73.0M | 6% |
| Other Industries | $15.9M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
